IN8bio, Inc. - INAB STOCK NEWS

Welcome to our dedicated page for IN8bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio stock.

IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of novel therapies aimed at treating various cancers. Using allogeneic, autologous, and genetically modified gamma-delta T cells, IN8bio is revolutionizing cancer treatment. The company’s mission is to create groundbreaking therapies that harness the power of the body’s immune system to target and destroy cancer cells.

IN8bio's robust portfolio includes several promising product candidates:

• INB-400: Aimed at treating newly diagnosed glioblastoma (GBM), this product is currently in a Phase 2 clinical trial.
• INB-100: Designed for patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, this therapy is under Phase 1 clinical trials.
• INB-200: Another promising candidate targeting GBM, it has shown encouraging preliminary clinical data at the 2024 ASCO Annual Meeting.
• Additional products, like INB-300 and INB-500, are in various stages of development targeting both solid and liquid tumors.

Recently, IN8bio disclosed significant advancements in the treatment of GBM, utilizing their innovative gamma-delta T cell-based adoptive cellular therapy. A peer-reviewed publication highlighted the strategy and future direction of their novel treatment methods.

Financially, IN8bio extends its cash runway into 2025, bolstered by additional capital from a private placement in December 2023. The company continues to pursue more funding to advance its clinical trials and achieve its milestones.

IN8bio's groundbreaking work has garnered attention in the biotech field, especially for its genetically modified gamma-delta T cells, which are the first to be advanced into clinical trials. The company’s approach shows great potential in improving progression-free survival (PFS) and overall survival (OS) rates for GBM and other cancers.

For investors and stakeholders, IN8bio provides exciting opportunities as it moves towards commercializing its therapies, aiming to address significant unmet medical needs in oncology. For more information, please visit IN8bio.